

Ref: FOI/GS/ID 7057

Please reply to:
FOI Administrator
Trust Management
Maidstone Hospital
Hermitage Lane
Maidstone, Kent
ME16 9QQ
Email: mtw-tr.foiadmin@nhs.net
www.mtw.nhs.uk

04 January 2022

Freedom of Information Act 2000

I am writing in response to your request for information made under the Freedom of Information Act 2000 in relation to biologic medications in gastroenterology.

You asked:

Q1. How many patients were treated in October 2021 (or latest available month) by the gastroenterology department with the following drugs:

- a. Adalimumab (any brand or biosimilar)*
- b. Infliximab (any brand or biosimilar)*
- c. Ustekinumab (Stelara)*
- d. Vedolizumab (Entyvio)*
- e. Tofacitinib (Xeljanz)*
- f. Filgotinib (Jyseleca)*

Q2. How many patients were treated in October 2021 (or latest available month) for Crohn's Disease ONLY with the following drugs:

- a. Adalimumab (any brand or biosimilar)*
- b. Infliximab (any brand or biosimilar)*
- c. Ustekinumab (Stelara)*
- d. Vedolizumab (Entyvio)*

Trust response:

The following information is for November 2021.

Q1.

- a. 133
- b. 96
- c. 22
- d. 90
- e. 7
- f. 0

Q2.

- a. 104
- b. 67
- c. 21
- d. 38